Phaseline

Companies › Sana Biotechnology

Sana Biotechnology: clinical trials, targets and expected readouts

1 active drug program in 26 registered trials: 13 Phase 2, 8 Phase 1, 3 Phase 4, 2 Phase 3; Neurology, Genitourinary, Hematology, Immunology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Lornoxicam (SC291)
Cyclooxygenase inhibitor
PTGS2, PTGS1Phase 1Lupus Erythematosus; Non Hodgkin's Lymphoma; Non Hodgkin Lymphoma; Preterm Premature Rupture of Membrane …Dec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06396078Lornoxicam (SC291)Phase 4Preterm Premature Rupture of MembraneOtherDec 2026
NCT05257018Lornoxicam (SC291)Phase 2Diffuse Large B-cell LymphomaOncologyDec 2026
NCT05696093Lornoxicam (SC291)Phase 3Ventilator Associated PneumoniaRespiratoryDec 2026
NCT06098326Lornoxicam (SC291)Phase 2Myelodysplastic SyndromesHematologyDec 2026
NCT06060782Lornoxicam (SC291)Phase 1Burkitt LymphomaOncologyDec 2026
NCT05126849Lornoxicam (SC291)Phase 2Refractory Idiopathic Aplastic AnemiaHematologyJan 2027
NCT04959175Lornoxicam (SC291)Phase 1Hematologic NeoplasmsOncologyApr 2027
NCT01192555Lornoxicam (SC291)Phase 1NeuroblastomaOncologyJun 2027
NCT05470491Lornoxicam (SC291)Phase 1HIVOncologyJul 2027
NCT06486337Lornoxicam (SC291)Phase 2NHLOncologyAug 2027
NCT06425133Lornoxicam (SC291)Phase 2Metastatic Colorectal CancerOncologySep 2027
NCT04576143Lornoxicam (SC291)Phase 2HER2-negative Breast CancerOncologySep 2027
NCT06800391Lornoxicam (SC291)Phase 2Pseudomyxoma PeritoneiOncologyNov 2027
NCT06294236Lornoxicam (SC291)Phase 1Lupus ErythematosusImmunologyDec 2027
NCT05544565Lornoxicam (SC291)Phase 4Pyelonephritis AcuteGenitourinaryJan 2028
NCT07652879Lornoxicam (SC291)Phase 2POEMS SyndromeNeurologyJan 2028
NCT07484633Lornoxicam (SC291)Phase 4InfectionInfectious diseaseAug 2028
NCT06176027Lornoxicam (SC291)Phase 1Relapsed Peripheral T-Cell LymphomasOncologySep 2028
NCT06285422Lornoxicam (SC291)Phase 1Non Hodgkin's LymphomaOncologyMar 2029
NCT06819592Lornoxicam (SC291)Phase 3All-cause MortalityNeurologyAug 2029
NCT05462613Lornoxicam (SC291)Phase 2Metastatic Colorectal CancerOncologyNov 2029
NCT07768436Lornoxicam (SC291)Phase 2Adenocarcinoma of the BreastOncologyAug 2030
NCT02579967Lornoxicam (SC291)Phase 2Primary T-cell Immunodeficiency DisordersInfectious diseaseDec 2031
NCT07214688Lornoxicam (SC291)Phase 2Allogeneic Stem Cell Transplant RecipientOtherJan 2032
NCT03852407Lornoxicam (SC291)Phase 2Acute Myeloid Leukemia in RemissionOncologyNov 2033
NCT05878184Lornoxicam (SC291)Phase 1Non Hodgkin LymphomaOncologyNov 2038

From the company's SEC filings

Cash and short-term investments of $122m on 2026-09-30; operating cash outflow about $146m a year; runway about 10 months at that burn, to Jul 2027; 4 of 6 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Specialist investors

Held by 4 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

PTGS2 (1) PTGS1 (1)

Companies with the same targets

ZetrOZ Caribou Biosciences Laboratorios Silanes S.A. de C.V. Brainfarma Industria Química e Farmacêutica S/A AFT Pharmaceuticals Sirnaomics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.